133 related articles for article (PubMed ID: 31350882)
1. Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis.
Kishi T; Sakuma K; Nomura I; Matsuda Y; Mishima K; Iwata N
Int J Neuropsychopharmacol; 2019 Nov; 22(11):698-709. PubMed ID: 31350882
[TBL] [Abstract][Full Text] [Related]
2. Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study: Brexpiprazole d'appoint pour l'engagement dans la vie des patients souffrant de trouble dépressif majeur: une étude interventionnelle canadienne ouverte de phase 4.
Therrien F; Ward C; Chokka P; Habert J; Ismail Z; McIntyre RS; MacKenzie EM
Can J Psychiatry; 2024 Jul; 69(7):513-523. PubMed ID: 38425284
[TBL] [Abstract][Full Text] [Related]
3. Effects of Adjunctive Brexpiprazole on Individual Depressive Symptoms and Functioning in Patients With Major Depressive Disorder and Anxious Distress: Post Hoc Analysis of Three Placebo-Controlled Studies.
McIntyre RS; Bubolic S; Zhang Z; MacKenzie EM; Therrien F; Miguelez M; Boucher M
J Clin Psychopharmacol; 2024 Mar-Apr 01; 44(2):133-140. PubMed ID: 38421922
[TBL] [Abstract][Full Text] [Related]
4. Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta-analysis.
Kishi T; Sakuma K; Saito T; Nakagawa A; Kato M; Iwata N
Neuropsychopharmacol Rep; 2024 Mar; 44(1):165-175. PubMed ID: 38219278
[TBL] [Abstract][Full Text] [Related]
5. Comparative Efficacy of Dopamine Partial Agonists by Doses for Treatment-Resistant Depression: A Systematic Review and Dose-Response Model-Based Network Meta-analysis.
Terao I; Kodama W
J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):413-417. PubMed ID: 38639435
[TBL] [Abstract][Full Text] [Related]
6. Role of adjunctive cariprazine for treatment-resistant depression in patients with major depressive disorder: A systematic review and meta-analysis of randomized controlled trials.
Ali E; Latif F; Mashkoor Y; Sheikh A; Iqbal A; Owais R; Ahmed J; Naveed S; Moeed A; Ullah I; Mughal S
Asian J Psychiatr; 2024 May; 95():104005. PubMed ID: 38513509
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of aripiprazole or bupropion augmentation and switching in patients with treatment-resistant depression or major depressive disorder: A systematic review and meta-analysis of randomized controlled trials.
Ji M; Feng J; Liu G
PLoS One; 2024; 19(4):e0299020. PubMed ID: 38669232
[TBL] [Abstract][Full Text] [Related]
8. Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta-analysis.
Kishi T; Sakuma K; Hatano M; Matsuda Y; Esumi S; Miyake N; Miura I; Hori H; Kato M; Iwata N
Neuropsychopharmacol Rep; 2024 Mar; 44(1):216-220. PubMed ID: 37646475
[TBL] [Abstract][Full Text] [Related]
9. Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis.
Kishi T; Sakuma K; Hatano M; Okumura T; Kato M; Baba H; Iwata N
Neuropsychopharmacol Rep; 2024 Mar; 44(1):267-271. PubMed ID: 38318955
[TBL] [Abstract][Full Text] [Related]
10. Zuranolone for treatment of major depressive disorder: a systematic review and meta-analysis.
Ahmad A; Awan AR; Nadeem N; Javed AS; Farooqi M; Daniyal M; Mumtaz H
Front Neurosci; 2024; 18():1361692. PubMed ID: 38726035
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive cariprazine as a novel effective strategy for treating major depressive disorder: A systematic review and meta-analysis.
Xie M; Qiu Y; Wang M; Wei X; Tao Y; Duan A; Shang J; Gao W; Wang Z
J Psychiatr Res; 2024 Apr; 172():71-80. PubMed ID: 38367320
[TBL] [Abstract][Full Text] [Related]
12. Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice.
Edinoff AN; Wu NW; Maxey BS; Ren AL; Leethy KN; Girma B; Odisho A; Kaye JS; Kaye AJ; Kaye AM; Kaye AD; Mychaskiw G; Viswanath O; Urits I
Psychopharmacol Bull; 2021 Mar; 51(2):69-95. PubMed ID: 34092824
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive cariprazine for major depressive disorder: a systematic review and meta-analysis.
Gill H; Chen-Li DCJ; Haikazian S; Seyedin S; McIntyre RS; Mansur RB; DiVincenzo JD; Phan L; Rosenblat JD
CNS Spectr; 2024 Apr; ():1-10. PubMed ID: 38555956
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of infliximab in treatment-resistant depression: A systematic review and meta-analysis.
Bavaresco DV; Uggioni MLR; Ferraz SD; Marques RMM; Simon CS; Dagostin VS; Grande AJ; da Rosa MI
Pharmacol Biochem Behav; 2020 Jan; 188():172838. PubMed ID: 31837338
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder.
Huang Q; Zhong X; Yun Y; Yu B; Huang Y
Neuropsychiatr Dis Treat; 2016; 12():2707-2714. PubMed ID: 27822042
[TBL] [Abstract][Full Text] [Related]
16. Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews.
Weiss C; Meehan SR; Brown TM; Gupta C; Mørup MF; Thase ME; McIntyre RS; Ismail Z
J Patient Rep Outcomes; 2021 Dec; 5(1):128. PubMed ID: 34894307
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of Zuranolone for treatment of depression: A systematic review and meta-analysis.
Fayoud AM; Orebi HA; Elshnoudy IA; Elsebaie MAT; Elewid MMM; Sabra HK
Psychopharmacology (Berl); 2024 Jul; 241(7):1299-1317. PubMed ID: 38802705
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's disease: a meta-analysis of randomized controlled trials.
Marinheiro G; Dantas JM; Mutarelli A; Menegaz de Almeida A; Monteiro GA; Zerlotto DS; Telles JPM
Neurol Sci; 2024 May; ():. PubMed ID: 38763935
[TBL] [Abstract][Full Text] [Related]
19. Association between duration of antidepressant treatment for major depressive disorder and relapse rate after discontinuation: A meta-analysis.
Hu Y; Xue H; Ni X; Guo Z; Fan L; Du W
Psychiatry Res; 2024 Jul; 337():115926. PubMed ID: 38733930
[TBL] [Abstract][Full Text] [Related]
20. Current level of evidence for improvement of antidepressant efficacy and tolerability by pharmacogenomic-guided treatment: A Systematic review and meta-analysis of randomized controlled clinical trials.
Milosavljević F; Molden PE; Ingelman-Sundberg PM; Jukić APMM
Eur Neuropsychopharmacol; 2024 Apr; 81():43-52. PubMed ID: 38340605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
